Optimal windows of statin use for immediate infarct limitation: 5′-Nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase

Circulation

Volumn 110, Issue 15, 2004, Pages 2143-2149

  Sanada, Shoji ^a   Asanuma, Hiroshi ^a   Minamino, Tetsuo ^a   Node, Koichi ^b   Takashima, Seiji ^a   Okuda, Hiroko ^a   Shinozaki, Yoshiro ^c   Ogai, Akiko ^d   Fujita, Masashi ^a   Hirata, Akio ^a   Kim, Jiyoong ^d   Asano, Yoshihiro ^a   Mori, Hidezo ^d   Tomoike, Hitonobu ^d   Kitamura, Soichiro ^d   Hori, Masatsugu ^a   Kitakaze, Masafumi ^d  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Adenosine; Enzymes; Myocardial infarction; Phosphates; Statins

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 5' NUCLEOTIDASE; 8 (4 SULFOPHENYL)THEOPHYLLINE; ALPHA,BETA METHYLENEADENOSINE TRIPHOSPHATE; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PITAVASTATIN; PRAVASTATIN; PROTEIN KINASE B; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY COLLATERAL CIRCULATION; DOG; ENZYME ACTIVATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE REPERFUSION; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; TIME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 5'-NUCLEOTIDASE; ADENOSINE TRIPHOSPHATE; ANDROSTADIENES; ANIMALS; CARDIOTONIC AGENTS; CHROMONES; CORONARY DISEASE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MORPHOLINES; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PRAVASTATIN; PYRIDINES; QUINOLINES; SIGNAL TRANSDUCTION; THEOPHYLLINE;

EID: 20844443811     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000143830.59419.73     Document Type: Article

References (43)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
3. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339: 1349-1357.
4. 4S Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
6. Lefer AM, Campbell B, Shin YK, et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 1999;100:178-184.
7. Ikeda Y, Young LH, Lefer AM. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol. 2003;41:649-656.
8. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
9. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol. 2003;41: 508-515.
10. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation. 2002;105:1368-1373.
11. Ledoux S, Laouari D, Essig M, et al. Lovastatin enhances ecto-5′-nucleotidase activity and cell surface expression in endothelial cells: implication of rho-family GTPases. Circ Res. 2002;90:420-427.
12. 1-Adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5′-nucleotidase activity. J Clin Invest. 1994;93: 2197-2205.
13. Kitakaze M, Minamino T, Node K, et al. Adenosine and cardioprotection in the diseased heart. Jpn Circ J. 1999;63:231-243.
14. Tuma PL, Finnegan CM, Yi JH, et al. Evidence for apical endocytosis in polarized hepatic cells: phosphoinositide 3-kinase inhibitors lead to the lysosomal accumulation of resident apical plasma membrane proteins. J Cell Biol. 1999;145:1089-1102.
15. Kitakaze M, Node K, Minamino T, et al. Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5′-nucleotidase. Circulation. 1996;93: 781-791.
16. Sanada S, Kitakaze M, Papst PJ, et al. Role of phasic dynamism of P38 mitogen-activated protein kinase activation in the ischemic preconditioning on the canine heart. Circ Res. 2001;88:175-180.
17. Kitakaze M, Minamino T, Funaya H, et al. Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart. Circulation. 1997;95:2108-2114.
18. Node K, Kitakaze M, Minamino T, et al. Activation of ecto-5′- nucleotidase by protein kinase C and its role in ischaemic tolerance in the canine heart. Br J Pharmacol. 1997;120:273-281.
19. Ogita H, Node K, Asanuma H, et al. Raloxifene improves coronary perfusion, cardiac contractility and myocardial metabolism in the ischemic heart: role of phosphatidylinositol 3-kinase/Akt pathway. J Cardiovasc Pharmacol. 2004;43:821-829.
20. Hilgendorff A, Muth H, Parviz B, et al. Statins differ in their ability to block NF-κB activation in human blood monocytes. Int J Clin Pharmacol Ther. 2003;41:397-401.
21. Kaneta S, Satoh K, Kano S, et al. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis. 2003;170:237-243.
22. Kitakaze M, Minamino T, Node K, et al. Activation of ecto-5′- nucleotidase and cardioprotection of ischemic preconditioning. Basic Res Cardiol. 1996;91:23-26.
23. Asanuma H, Kitakaze M, Funaya H, et al. Nifedipine limits infarct size via NO-dependent mechanisms in dogs. Basic Res Cardiol. 2001;96: 497-505.
24. Lefer AM, Lefer DJ. Nitric oxide, II: nitric oxide protects in intestinal inflammation. Am J Physiol. 1999;276:G572-G575.
25. Massberg S, Sausbier M, Klatt P, et al. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′,5′- monophosphate kinase I. J Exp Med. 1999;189:1255-1264.
26. Agullo L, Garcia-Dorado D, Inserte J, et al. L-Arginine limits myocardial cell death secondary to hypoxia-reoxygenation by a cGMP-dependent mechanism. Am J Physiol. 1999;276:H1574-H1580.
27. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res. 1999;43: 860-878.
28. Buras JA, Stahl GL, Svoboda KK, et al. Hyperbaric oxygen down-regulates ICAM-1 expression induced by hypoxia and hypoglycemia: the role of NOS. Am J Physiol Cell Physiol. 2000;278:C292-C302.
29. Weiland U, Haendeler J, Ihling C, et al. Inhibition of endogenous nitric oxide synthase potentiates ischemia-reperfusion-induced myocardial apoptosis via a caspase-3 dependent pathway. Cardiovasc Res. 2000;45: 671-679.
30. Dorheim TA, Hoffman A, Van Wylen DG, et al. Enhanced interstitial fluid adenosine attenuates myocardial stunning. Surgery. 1991;110: 136-145.
31. Babbitt DG, Virmani R, Vildibill HD Jr, et al. Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow. Am Heart J. 1990;120:808-818.
32. Norton ED, Jackson EK, Virmani R, et al. Effect of intravenous adenosine on myocardial reperfusion injury in a model with low myocardial collateral blood flow. Am Heart J. 1991;122:1283-1291.
33. Richardt G, Waas W, Kranzhofer R, et al. Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia. Circ Res. 1987;61:117-123.
34. Sato H, Hori M, Kitakaze M, et al. Endogenous adenosine blunts β-adrenoceptor-mediated inotropic response in hypoperfused canine myocardium. Circulation. 1992;85:1594-1603.
35. Cronstein BN, Levin RI, Belanoff J, et al. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest. 1986;78:760-770.
36. Kitakaze M, Hori M, Sato H, et al. Endogenous adenosine inhibits platelet aggregation during myocardial ischemia. Circ Res. 1991;69:1402-1408.
37. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res. 2004;61:448-460.
38. 3 adenosine receptor regulation. Biochim Biophys Acta. 2002;1591:55-62.
39. Yang XM, Krieg T, Cui L, et al. NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through P13K, ERK, and NO. J Mol Cell Cardiol. 2004;36:411-421.
40. Boucher M, Pesant S, Falcao S, et al. Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathway. J Cardiovasc Pharmacol. 2004;43:416-422.
41. Kawasaki K, Smith RS Jr, Hsieh CM, et al. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol. 2003;23:5726-5737.
42. Richardt G, Waas W, Kranzhofer R, et al. Interaction between the release of adenosine and noradrenaline during sympathetic stimulation: a feed-back mechanism in rat heart. J Mol Cell Cardiol. 1989;21:269-277.
43. Buga GM, Griscavage JM, Rogers NE, et al. Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res. 1993;73: 808-812.